A blood test for cancer: ask the question first
A new lesion, and the team wants a target
Three questions, three families
Which drug?
Advanced cancer. Reads hundreds of genes in the blood. No tissue needed.
Guardant360 Liquid, FoundationOne Liquid CDx, Tempus xF, Caris Assure
Is it still there?
After curative treatment. Follows one known cancer over time.
Signatera, Guardant Reveal, NeXT Personal, RaDaR, Oncodetect
Is there a cancer at all?
People with no cancer and no symptoms. Screening.
Shield, Galleri
Signatera never reports a new target. A broad panel is too shallow to call a patient clear.
Where the tube runs quiet
Order it from clinic, not from the ward
The result takes 1 to 3 weeks, so it rarely changes anything during the admission. The same rule catches a surgical specimen sent for testing within 14 days of discharge. If the result will change treatment before discharge, order it. The rule is about billing, not about care.
What changes treatment today
ESR1 in breast cancer.
Bladder cancer after cystectomy: Signatera selects atezolizumab.
Large B-cell lymphoma: a PET-positive scan at the end of treatment.
Following response to immunotherapy.
ASCO 2026: do not use the amount of tumor DNA in blood as a stand-in for tumor burden. It is prognostic (prostate: tumor fraction above 30% carries 5.6 times the risk of death), not a measurement.
The screening family, briefly
- Shield (Guardant): FDA approved in July 2024 for colorectal cancer screening at average risk, age 45 or older. It found 83% of colorectal cancers and 13% of advanced polyps, with 90% specificity. Stage I detection was 55% (12 of 22 cancers; the interval runs from 35 to 73%).
- Galleri (GRAIL): reads methylation patterns for many cancers at once. Specificity 99.5%; sensitivity 17% in stage I, 40% in stage II, 77% in stage III, 90% in stage IV. When positive, 38 to 60% turned out to be cancer.
- The randomized NHS trial of 142,250 people did not reduce stage III or IV diagnoses of 12 prespecified cancers after three annual screens (rate ratio 1.03); for stage IV alone it was 0.86 (0.74 to 1.00), not significant.
- Galleri is not FDA approved as of October 2026. An advisory panel voted on September 23, 2026: unanimous on safety, 6 to 4 on effectiveness, 7 to 2 on benefit over risk.
Sources
Retrieved from PubMed (abstracts), FDA records, product labels and the Medicare rule itself. Items dated 2026 come from FDA and news pages read on Oct 15, 2026.
- Aldea M, et al. Circulating tumor DNA with isolated central nervous system progression. J Thorac Oncol 2020. doi:10.1016/j.jtho.2019.11.024
- Lee JH, et al. Circulating tumor DNA and intracranial melanoma. Clin Cancer Res 2020. doi:10.1158/1078-0432.CCR-19-3926
- CMS laboratory date of service policy. Policy. Regulation: 42 CFR 414.510
- Lockwood CM, et al. ASCO guideline on circulating tumor DNA. JCO Oncol Pract 2026. doi:10.1200/OP-26-00311
- Chung DC, et al. ECLIPSE: a cell-free DNA blood test for colorectal cancer screening. N Engl J Med 2024. doi:10.1056/NEJMoa2304714
- Shield provider labeling. Label
- Klein EA, et al. Validation of a multi-cancer early detection test. Ann Oncol 2021. doi:10.1016/j.annonc.2021.05.806
- Schrag D, et al. PATHFINDER. Lancet 2023. doi:10.1016/S0140-6736(23)01700-2
- Nabavizadeh N, et al. PATHFINDER 2. Nat Med 2026. doi:10.1038/s41591-026-04618-w
- Sasieni P, et al. NHS-Galleri randomized trial. N Engl J Med 2026. doi:10.1056/NEJMoa2505723
Guardant360 Liquid and FoundationOne Liquid: reading the blood for a target
Most of the DNA in the tube is not tumor
Two numbers, often confused. Tumor fraction: how much of all the DNA is tumor. Allele fraction: at one gene position, the share of fragments that carry the mutation.
Reading the report
A BRCA2 mutation in plasma: three possible origins
"Somatic" covers the last two, and they mean opposite things. In breast and pancreatic cancer the PARP inhibitor approvals require an inherited mutation.
Nothing found
What plasma misses
The two tests
Guardant360 Liquid CDx
741 genes. FDA approved May 2026; it replaced the 55-gene version of 2020.
FDA-approved as the test for a drug in: lung (EGFR, KRAS G12C, HER2), breast (ESR1), colorectal (BRAF)
FoundationOne Liquid CDx
311 genes reported, 324 read. FDA approved August 2020.
FDA-approved as the test for a drug in: lung (EGFR, ALK, ROS1, MET, BRAF), prostate (BRCA, ATM and other repair genes), breast (PIK3CA), colorectal (BRAF), any tumor (NTRK)
Both profile every gene on the panel in any solid tumor: BRAF in melanoma, RET in thyroid cancer and the rest. Those results are profiling. The list above is narrower: the cancers where the FDA approved the blood test itself to select the drug. For melanoma and thyroid cancer the approved tests are still tissue tests.
Neither sequences white cells, so neither can tell a blood-cell mutation from a tumor mutation. Caris Assure does. Tempus xF (105 genes) and xF+ (523) are widely used and are not on the FDA list.
The numbers
- Blood-cell mutations: in 69 men with prostate cancer whose plasma and white cells were both sequenced, 7 (10%) had a mutation in a PARP inhibitor gene that came from a blood-cell clone, not from the tumor: ATM in 5, BRCA2 in 1, CHEK2 in 1. Of 23 repair-gene variants that looked positive on plasma alone, 8 came from a blood-cell clone; of the 15 that were real, 9 were from the tumor and 6 were inherited.
- Inherited findings: about 1.4% of Guardant360 reports carried a probable germline variant.
- Lung cancer, 282 patients, Guardant360: plasma found a guideline biomarker in 77 patients, tissue in 60, both together in 89. All 34 plasma positives for approved targets were real. Results in 9 days versus 15.
- Detection limits are not comparable between the two tests. Guardant: an allele fraction of 0.2% for key variants at full DNA input, about 1% at low input. Foundation: 0.40% in its high-sensitivity regions, 0.82% elsewhere.
- Two vendors, same patients: in 40 men with metastatic prostate cancer tested by Guardant360 and PlasmaSELECT, the two reports agreed completely on a finding in 3, partly in 6, and not at all in 16 (9 more agreed only that nothing was found).
- Plasma is strong at progression, when new resistance mutations appear. In breast cancer, Guardant360 every 2 to 3 months caught ESR1 mutations before progression; switching to camizestrant then gave 16.0 versus 9.2 months without progression (hazard ratio 0.44).
Sources
Retrieved from PubMed (abstracts) and from FDA documents, which were read in full. The row-by-row FDA drug pairings were taken from the list dated September 28, 2026.
- Jensen K, et al. Clonal hematopoiesis in cell-free DNA testing for prostate cancer. JAMA Oncol 2021. doi:10.1001/jamaoncol.2020.5161
- de Bono J, et al. Olaparib for metastatic castration-resistant prostate cancer (PROfound). N Engl J Med 2020. doi:10.1056/NEJMoa1911440
- Slavin TP, et al. Incidental germline variants in plasma cell-free DNA. J Clin Oncol 2018. doi:10.1200/JCO.18.00328
- Rolfo CD, et al. Tumor fraction identifies informative negative liquid biopsy results. Clin Cancer Res 2024. doi:10.1158/1078-0432.CCR-23-3321
- Leighl NB, et al. NILE: plasma versus tissue genotyping in advanced lung cancer. Clin Cancer Res 2019. doi:10.1158/1078-0432.CCR-19-0624
- Mondaca S, et al. Plasma detection of ALK fusions. Lung Cancer 2021. doi:10.1016/j.lungcan.2021.06.018
- Chi KN, et al. Plasma detection of BRCA and ATM alterations in PROfound. Clin Cancer Res 2023. doi:10.1158/1078-0432.CCR-22-0931
- FDA summary, Guardant360 Liquid CDx, P250027. Document
- FDA summary, FoundationOne Liquid CDx, P190032. Document
- FDA list of cleared or approved companion diagnostic devices. List
- Torga G, Pienta KJ. Patient-paired comparison of two commercial liquid biopsy tests. JAMA Oncol 2018. doi:10.1001/jamaoncol.2017.4027
- Bidard FC, et al. SERENA-6: camizestrant on emergence of ESR1 mutation. N Engl J Med 2025. doi:10.1056/NEJMoa2502929
- Abraham J, et al. Validation of Caris Assure. Sci Rep 2025. doi:10.1038/s41598-025-08986-0
Signatera: a test built from the patient's own tumor
How it is built
Because it looks in only 16 known places, it can read each one very deeply: the manufacturer's stated limit is in the range of 1 mutant fragment in 10,000 (not independently verified). A broad panel needs about 1 in 100 to 500. The price: it can never see a mutation the first tumor did not have.
When to draw
Healing tissue floods the blood with normal DNA for up to 4 weeks and can hide the tumor signal.
The trial that turned it into a treatment decision
IMvigor011. The FDA approved atezolizumab for this use in May 2026, with Signatera as the required test. The benefit was seen when the test turned positive within 20 weeks of surgery (hazard ratio 0.52), not later (1.04, an exploratory analysis).
Read it as a series
One negative lowers the risk. It does not rule out relapse: 74 of the 250 randomized bladder patients first turned positive more than 20 weeks after surgery.
What a result means, by cancer
The numbers
- Logistics (manufacturer): first report within 3 weeks in 90% of cases, later reports within 1 week. Two 10 mL tubes (from Natera ordering materials, not from the page cited).
- Who was in the bladder trial: eligibility is in the tree above. About half had received neoadjuvant chemotherapy.
- Colorectal, 2,240 patients followed in Japan: a positive test after surgery carried about 12 times the risk of relapse. Not randomized.
- Colorectal, randomized: 243 positive patients received trifluridine/tipiracil or placebo. Relapse-free time 9.3 versus 5.6 months, hazard ratio 0.79, not significant, with far more toxicity. About 1 in 10 placebo patients turned negative without treatment.
- Built from the tumor or not: with repeated samples in colorectal cancer, tests built from the tumor caught 88% of relapses and tissue-free tests 59%. With a single sample after surgery they did not differ.
- Breast: the test turned positive before 16 of 18 relapses, a median of 8.9 months ahead. In a later trial about half of first positives already had a relapse visible on imaging.
- Kidney cancer sheds little: the test was positive before surgery in 18 of 36 patients.
- Medicare covers it for colorectal, breast, bladder, lung and ovarian cancer, and for immunotherapy monitoring in any solid tumor (manufacturer's list, not rechecked).
- Outside bladder cancer, residual disease testing is not yet routine care (ESMO 2022; ASCO 2026 asks for an evidence-based action tied to the result).
Sources
Retrieved from PubMed. The 2019 colorectal study and the 2026 randomized colorectal trial were read in full text; the rest as abstracts. The bladder trial schedule, eligibility and timing analysis come from the FDA approval notice and the label text, read on Oct 15, 2026.
- Reinert T, et al. Circulating tumor DNA in stages I to III colorectal cancer. JAMA Oncol 2019. doi:10.1001/jamaoncol.2019.0528
- Powles T, et al. IMvigor011: atezolizumab guided by circulating tumor DNA in bladder cancer. N Engl J Med 2025. doi:10.1056/NEJMoa2511885
- FDA approval of adjuvant atezolizumab for bladder cancer with molecular residual disease, May 2026. FDA notice
- Henriksen TV, et al. The effect of surgical trauma on circulating free DNA levels. Mol Oncol 2020. doi:10.1002/1878-0261.12729
- Nakamura Y, et al. Circulating tumor DNA and outcomes in resected colorectal cancer (GALAXY). Nat Med 2024. doi:10.1038/s41591-024-03254-6
- Bando H, et al. ALTAIR: trifluridine/tipiracil for circulating tumor DNA positive colorectal cancer. Nat Med 2026. doi:10.1038/s41591-026-04428-0
- Camblor DG, et al. Tumor-informed versus tumor-agnostic residual disease assays, meta-analysis. Cancer Treat Rev 2026. doi:10.1016/j.ctrv.2025.103066
- Coombes RC, et al. Personalized detection of circulating tumor DNA antedates breast cancer recurrence. Clin Cancer Res 2019. doi:10.1158/1078-0432.CCR-18-3663
- ZEST trial report, 2024. ASCO Post
- Bratman SV, et al. Personalized circulating tumor DNA analysis and pembrolizumab. Nat Cancer 2020. doi:10.1038/s43018-020-0096-5
- Correa AF, et al. Circulating tumor DNA in renal cell carcinoma. Oncologist 2024. doi:10.1093/oncolo/oyae180
- Pascual J, et al. ESMO recommendations on circulating tumour DNA assays. Ann Oncol 2022. doi:10.1016/j.annonc.2022.05.520
- Lockwood CM, et al. ASCO guideline on circulating tumor DNA. JCO Oncol Pract 2026. doi:10.1200/OP-26-00311
- Signatera product and coverage page, Natera. Page
Every test by name
One company, several tests
Only the blood tests discussed here, plus the tissue tests most often confused with them.
The trial you quote used this test
- IMvigor011, bladder: Signatera.
- GALAXY and ALTAIR, colorectal: Signatera.
- DYNAMIC, colon stage II: a Johns Hopkins research assay, not Signatera.
- COBRA, colon stage IIA: an early Guardant assay. Stopped, because chemotherapy did not clear the blood more often than observation.
- NILE (lung), EMERALD and SERENA-6 (breast): Guardant360.
- PROfound plasma analysis, prostate: FoundationOne Liquid.
The other residual disease tests
- NeXT Personal (Personalis): built from the whole genome of the tumor, follows about 1,800 mutations.
- Oncodetect (Exact Sciences): up to 200 mutations. RaDaR ST (NeoGenomics): up to 48.
- FoundationOne Tracker: built by Natera from the FoundationOne CDx tissue result.
- Guardant Reveal and Tempus xM need no tissue. They read methylation patterns. Reveal's sensitivity for relapse was 100% in liver, 53% in lung and 40% in peritoneum.
- Following more mutations lets a test see smaller amounts of tumor. The makers' stated limits have not been compared in one study.
Sources
Retrieved from PubMed (abstracts), the FDA companion diagnostics list and company pages read on Oct 15, 2026. Product names and coverage change often.
- FDA list of cleared or approved companion diagnostic devices. List
- Tie J, et al. DYNAMIC. N Engl J Med 2022. doi:10.1056/NEJMoa2200075
- COBRA (NRG-GI005) report, 2024. ASCO Post
- Bidard FC, et al. EMERALD. J Clin Oncol 2022. doi:10.1200/JCO.22.00338
- Matsubara N, et al. Olaparib efficacy by circulating tumor DNA in PROfound. Clin Cancer Res 2023. doi:10.1158/1078-0432.CCR-21-3577
- Nakamura Y, et al. COSMOS: tissue-free residual disease detection in colorectal cancer. Clin Cancer Res 2024. doi:10.1158/1078-0432.CCR-24-1651
- Black JRM, et al. Ultrasensitive circulating tumor DNA detection in early lung cancer (TRACERx). Nat Med 2025. doi:10.1038/s41591-024-03216-y
- Company pages: Signatera, Guardant Reveal, RaDaR ST, Oncodetect, Tempus xM
By cancer: what a blood test does today
The board
Colors on this board mean something different from the By name tab: blue is a result that changes treatment today, gray is prediction only or no useful data (the cell says which), orange is where blood misleads.
Other cancers
Open a cancer below for the numbers. "Changes treatment" means an FDA-approved drug match in plasma, an FDA-approved use, or an accepted standard.
Lung
- Plasma drug matches on the FDA list: EGFR (including exon 20), ALK, ROS1, MET exon 14, BRAF V600E, KRAS G12C and HER2 mutation, split between the two panels.
- After surgery, 197 patients: blood was positive within 120 days in 25%. That single test caught only 49% of those who later relapsed.
- Clearing the blood during neoadjuvant chemo-immunotherapy goes with survival: 75% versus 53% alive at 5 years. This is prognosis; no trial has changed treatment on it.
- After chemoradiation, blood drawn before durvalumab did not predict outcome; later draws did.
- Progression only in the brain: plasma often negative (Aldea 2020, figure on the Start here tab).
Breast
- ESR1 in blood selects elacestrant and its successors. Testing every 2 to 3 months and switching to camizestrant at the first ESR1 mutation worked in SERENA-6 (numbers on the Which drug tab).
- PIK3CA in blood is an approved match for alpelisib. The approved test for capivasertib is tissue.
- HER2: no approved plasma test. In one series plasma agreed with tissue in 87%.
- Surveillance has not worked so far. In triple-negative disease, 23 of 32 patients already had metastases on scans when the blood turned positive. In high-risk ER-positive disease, blood turned positive in 12%, and 43% of those were already metastatic.
Colorectal
- BRAF V600E in plasma is an approved match for encorafenib with cetuximab.
- Giving an anti-EGFR antibody again: when RAS, BRAF and EGFR mutations had cleared from blood, 8 of 27 patients responded to panitumumab. A third of those screened still carried a mutation and were spared the drug.
- After surgery: a positive test is a strong predictor of relapse (GALAXY, numbers on the Still there tab). In stage II, letting blood decide halved chemotherapy use with the same outcome. In stage III the same strategy failed, and a drug added for positive patients did not help.
- RAS in plasma agreed with tissue in 77%.
Stomach and esophagus, pancreas, bile duct, liver
- Stomach and esophagus: in patients who were HER2-positive on tissue, plasma found the amplification in only 62% (36 of 58). Tissue and plasma together found more HER2, EGFR, FGFR2 and MET alterations than either alone. After surgery, Signatera was positive in 16 of 68 patients and carried about 10 times the risk of relapse. Peritoneal-only disease is often undetectable.
- Pancreas: tumor DNA is found in 48% of localized and over 75% of advanced cancers. At relapse visible on scans, Signatera was positive in 9 of 18. The approved test for olaparib is a blood test of inherited DNA, not tumor DNA.
- Pancreas, BRCA reversions after rucaparib: found in 5 of 30, with 3.7 versus 12.5 months without progression.
- Bile duct, 1,671 patients tested by Guardant360: a targetable alteration in 44%. Agreement with tissue was 87% for IDH1, 100% for BRAF V600E and 18% for FGFR2 fusions. A negative plasma test does not exclude a fusion.
- Liver: one surveillance blood test was 85% sensitive in its first study and 48% when tested prospectively against MRI, with 29% for tumors of 2 cm or less. That still beat ultrasound (28%), at lower specificity. No outcome data.
Prostate
- FoundationOne Liquid CDx is the plasma test on the FDA list for the PARP inhibitors. It agreed with tissue for only 27% of two-copy BRCA deletions.
- A tumor fraction above 30% carried 5.6 times the risk of death of one below 2%. This is prognosis, not a way to measure response.
Bladder, kidney
- Bladder: the chain above is IMvigor011 (figure and hazard ratios on the Still there tab). Trial population: pT2 to 4a or node-positive, enrolled 6 to 24 weeks after cystectomy, no adjuvant chemotherapy or radiation, and, if no neoadjuvant cisplatin, not a candidate for adjuvant cisplatin or declined it. No data after perioperative immunotherapy.
- Bladder: FGFR3 for erdafitinib is tested on tumor tissue; no blood or urine test is approved. Urine tumor DNA after BCG predicts relapse and does not yet change treatment.
- Kidney: with the tumor still in place, tumor DNA was found in 28% by standard sequencing and in 18 of 36 by Signatera. A negative after nephrectomy says little.
Melanoma, Merkel cell, other skin
- Melanoma with brain metastases: blood is negative when the disease is in the brain only (Lee 2020, figure on the Start here tab); with disease in the body as well it was positive in 64%.
- Melanoma after resection of stage III: BRAF was detectable in blood in 13%, with about 3 times the hazard of relapse.
- Merkel cell, 319 patients tested with Signatera: in patients who had disease at enrollment it was positive in 94 to 95%. During surveillance a positive test predicted relapse within a year in 69% (discovery) and 94% (validation), and a negative test was right 93 to 94% of the time at 135 days. In a later paired study it outperformed the viral antibody test.
- Squamous cell skin cancer: nothing established.
Ovary, uterus, cervix
- No plasma drug match today. The plasma approval for rucaparib in ovarian cancer lapsed when that indication was withdrawn.
- BRCA reversion mutations in blood before rucaparib: in 18% of platinum-refractory, 13% of platinum-resistant and 2% of platinum-sensitive cancers. Time without progression was 1.8 months with a reversion, 9.0 without.
- Ovary, 25 patients followed after treatment with Signatera: tumor DNA was found only in those who relapsed, on average 10 months before imaging. CA-125 did not predict.
- Cervix: HPV DNA still in blood 3 months after chemoradiation meant 24% progression-free at 2 years, against 82%.
- Uterus, stage I: relapse in 58% when blood was positive, 6% when negative.
Head and neck
- NavDx reads fragments of HPV DNA that carry the pattern of tumor origin. It is not FDA cleared; Medicare covers it.
- In surveillance of HPV throat cancer, a negative test was right 95 to 100% of the time. Two positives in a row predicted relapse in 94%. After a single positive, 15 of 28 relapsed.
- Nasopharynx: EBV DNA in blood after radiotherapy strongly predicts relapse. Giving adjuvant chemotherapy to those patients did not help in a randomized trial (hazard ratio 1.09).
- Nasopharynx screening where the cancer is common: 97% sensitive among 20,174 people, with 71% of cancers found at stage I or II.
Lymphoma, myeloma, leukemia
- Large B-cell lymphoma at the end of treatment, 137 patients: 29% progression-free at 2 years when tumor DNA was detectable, 97% when it was not. It predicted better than PET.
- US guidelines (NCCN) now accept an ultrasensitive blood test in place of a biopsy for a PET-positive scan at the end of treatment.
- Hodgkin lymphoma: tumor DNA after 2 cycles predicts outcome. Prognosis only.
- clonoSEQ reads the gene rearrangement that identifies the clone. FDA cleared for myeloma and B-cell acute lymphoblastic leukemia on marrow, and for chronic lymphocytic leukemia on blood or marrow. Its lymphoma uses are not FDA cleared.
- Myeloma: marrow is still required. A blood protein method agreed with marrow in 70%.
- Chronic myeloid leukemia: BCR::ABL1 measured in blood is the original liquid biopsy and decides when to switch or stop.
Brain tumors, sarcoma, thyroid, any solid tumor
- Brain tumors: tumor DNA is found in plasma in under 10% of gliomas and in spinal fluid in 42 of 85. No approved use.
- Sarcoma: tests built from the tumor found it in 85% of localized soft tissue sarcomas and predicted outcome. Nothing changes treatment.
- Thyroid: RET and BRAF drug matches are tissue tests. Under half of metastatic thyroid cancers shed detectable DNA.
- Any solid tumor: an NTRK fusion in plasma is an approved match for entrectinib (FoundationOne Liquid CDx), to be used when tissue is not available.
- Microsatellite instability and mutation burden are reported from blood by both panels, but no plasma test is FDA-approved to select pembrolizumab. RET for selpercatinib is tissue only.
Sources
Retrieved from PubMed and read as abstracts unless noted. FDA drug matches come from the companion diagnostics list.
- FDA list of cleared or approved companion diagnostic devices. List
- Abbosh C, et al. Tracking early lung cancer metastatic dissemination in TRACERx. Nature 2023. doi:10.1038/s41586-023-05776-4
- Forde PM, et al. CheckMate 816, 5-year results. N Engl J Med 2025. doi:10.1056/NEJMoa2502931
- Horndalsveen H, et al. Circulating tumor DNA around chemoradiation and durvalumab. J Thorac Oncol 2026. doi:10.1016/j.jtho.2026.103992
- Aldea M, et al. J Thorac Oncol 2020. doi:10.1016/j.jtho.2019.11.024
- Bidard FC, et al. SERENA-6. N Engl J Med 2025. doi:10.1056/NEJMoa2502929
- Guan X, et al. HER2 amplification in plasma. Breast 2020. doi:10.1016/j.breast.2019.12.010
- Turner NC, et al. c-TRAK TN. Ann Oncol 2023. doi:10.1016/j.annonc.2022.11.005
- TRAK-ER and other surveillance trials, ESMO Breast 2026. ESMO Daily Reporter
- Sartore-Bianchi A, et al. CHRONOS. Nat Med 2022. doi:10.1038/s41591-022-01886-0
- Nakamura Y, et al. GALAXY. Nat Med 2024. doi:10.1038/s41591-024-03254-6
- Tie J, et al. DYNAMIC. N Engl J Med 2022. doi:10.1056/NEJMoa2200075. DYNAMIC-III: Nat Med 2025. doi:10.1038/s41591-025-04030-w
- Bando H, et al. ALTAIR. Nat Med 2026. doi:10.1038/s41591-026-04428-0
- Osumi H, et al. RAS in plasma and tissue. Cancer Med 2019. doi:10.1002/cam4.1913
- Maron SB, et al. Circulating tumor DNA in gastroesophageal adenocarcinoma. Clin Cancer Res 2019 (full text). doi:10.1158/1078-0432.CCR-19-1704
- Huffman BM, et al. Signatera in esophagogastric cancer. JCO Precis Oncol 2022. doi:10.1200/PO.22.00420
- Bettegowda C, et al. Detection of circulating tumor DNA in early- and late-stage malignancies. Sci Transl Med 2014. doi:10.1126/scitranslmed.3007094
- Eckhoff AM, et al. Signatera in pancreatic cancer. Ann Surg Oncol 2024. doi:10.1245/s10434-023-14751-2
- Brown TJ, et al. BRCA reversions after rucaparib in pancreatic cancer. Clin Cancer Res 2023. doi:10.1158/1078-0432.CCR-23-1467
- Berchuck JE, et al. Cell-free DNA in advanced biliary tract cancer. Ann Oncol 2022. doi:10.1016/j.annonc.2022.09.150
- Lin N, et al. Hepatol Commun 2022. doi:10.1002/hep4.1918. Taggart, et al. J Hepatol 2026. doi:10.1016/j.jhep.2026.04.012
- Hussain M, et al. Clin Cancer Res 2022. doi:10.1158/1078-0432.CCR-21-3940. Matsubara N, et al. Clin Cancer Res 2023. doi:10.1158/1078-0432.CCR-21-3577. Chi KN, et al. Clin Cancer Res 2023. doi:10.1158/1078-0432.CCR-22-0931
- Jensen K, et al. JAMA Oncol 2021. doi:10.1001/jamaoncol.2020.5161
- Fonseca NM, et al. Nat Commun 2024 (full text). doi:10.1038/s41467-024-45475-w
- Powles T, et al. IMvigor011. N Engl J Med 2025. doi:10.1056/NEJMoa2511885
- Bahlburg H, et al. Urine tumor DNA after BCG. J Urol 2026. doi:10.1097/JU.0000000000005130
- Smith CG, et al. Genome Med 2020. doi:10.1186/s13073-020-00723-8. Correa AF, et al. Oncologist 2024. doi:10.1093/oncolo/oyae180
- Lee JH, et al. Clin Cancer Res 2020. doi:10.1158/1078-0432.CCR-19-3926. Syeda MM, et al. Lancet Oncol 2025. doi:10.1016/S1470-2045(25)00139-1
- Akaike T, et al. Circulating tumor DNA in Merkel cell carcinoma. J Clin Oncol 2024. doi:10.1200/JCO.23.02054. Thakuria M, et al. JAMA Dermatol 2026. doi:10.1001/jamadermatol.2026.2153
- Lin KK, et al. BRCA reversion mutations in circulating tumor DNA (ARIEL2). Cancer Discov 2019. doi:10.1158/2159-8290.CD-18-0715
- Hou JY, et al. Signatera in ovarian cancer. Gynecol Oncol 2022. doi:10.1016/j.ygyno.2022.09.004
- Han K, et al. HPV DNA after chemoradiation for cervical cancer. J Clin Oncol 2024. doi:10.1200/JCO.23.00954. Recio F, et al. Gynecol Oncol 2024. doi:10.1016/j.ygyno.2023.12.025
- Chera BS, et al. Plasma HPV DNA in surveillance of oropharyngeal cancer. J Clin Oncol 2020. doi:10.1200/JCO.19.02444. Berger BM, et al. Clin Cancer Res 2022. doi:10.1158/1078-0432.CCR-22-0562. Hanna GJ, et al. Clin Cancer Res 2023. doi:10.1158/1078-0432.CCR-23-1478
- Chan ATC, et al. Adjuvant chemotherapy by plasma EBV DNA in nasopharyngeal carcinoma. J Clin Oncol 2018. doi:10.1200/JCO.2018.77.7847. Chan KCA, et al. Screening. N Engl J Med 2017. doi:10.1056/NEJMoa1701717
- Roschewski M, et al. End-of-treatment circulating tumor DNA in large B-cell lymphoma. J Clin Oncol 2025. doi:10.1200/JCO-25-01534. Guideline report: OncLive, 2025
- Heger JM, et al. Circulating tumor DNA in Hodgkin lymphoma. Blood 2026. doi:10.1182/blood.2025031089
- clonoSEQ technical summary. Page. Kubicki T, et al. Blood and marrow residual disease in myeloma. Blood 2024. doi:10.1182/blood.2024024041
- Miller AM, et al. Tracking tumour evolution in glioma through cerebrospinal fluid. Nature 2019. doi:10.1038/s41586-019-0882-3
- Subramanian A, et al. Circulating tumor DNA in soft tissue sarcoma. J Clin Oncol 2026. doi:10.1200/JCO-26-00769
- FoundationOne Liquid CDx indications. Page